@article{4508332507e4447f811ba645484f3040,
title = "Ocrelizumab Concentration Is a Good Predictor of SARS-CoV-2 Vaccination Response in Patients with Multiple Sclerosis",
abstract = "Ocrelizumab, an anti-CD20 monoclonal antibody, counteracts induction of humoral immune responses after severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) vaccinations in patients with multiple sclerosis (MS). We aimed to assess if serum ocrelizumab concentration measured at the time of vaccination could predict the humoral response after SARS-CoV-2 vaccination. In 52 patients with MS, we found ocrelizumab concentration at the time of vaccination to be a good predictor for SARS-CoV-2 IgG anti-RBD titers after vaccination (comparable to B-cell count). As the course of ocrelizumab concentration may be predicted using pharmacokinetic models, this may be a superior biomarker to guide optimal timing for vaccinations in B-cell depleted patients with MS. ANN NEUROL 2023;93:103–108.",
keywords = "Antibodies, Viral, COVID-19, COVID-19 Vaccines, Humans, Multiple Sclerosis/drug therapy, SARS-CoV-2",
author = "{van Kempen}, {Zo{\'e} L. E.} and Laura Hogenboom and Toorop, {Alyssa A.} and Maurice Steenhuis and Stalman, {Eileen W.} and Kummer, {Laura Y. L.} and {van Dam}, {Koos P. J.} and Karien Bloem and {ten Brinke}, Anja and {van Ham}, {S. Marieke} and Kuijpers, {Taco W.} and Wolbink, {Gerrit J.} and Loeff, {Floris C.} and {the T2B! immunity against SARS-CoV-2 study group} and Luuk Wieske and Filip Eftimov and Theo Rispens and Strijbis, {Eva M. M.} and Joep Killestein and {T2B! immunity against SARS-CoV-2 study group}",
note = "Funding Information: The authors are grateful for ZonMw (The Netherlands Organization for Health Research and Development) for funding this study (grant number 10,430,072,010,007). The sponsor had no role in the design, analyses, or reporting of the study. We are also grateful for the Dutch MS Research Foundation for additional funding of this study (grant number 21‐1135 MS). Funding Information: J.K. reported speaking and consulting relationships with Roche, this company manufactures ocrelizumab. Amsterdam UMC, location VUmc, MS Center Amsterdam has received financial support for research activities from Roche. Publisher Copyright: {\textcopyright} 2022 The Authors. Annals of Neurology published by Wiley Periodicals LLC on behalf of American Neurological Association.",
year = "2023",
month = jan,
doi = "https://doi.org/10.1002/ana.26534",
language = "English",
volume = "93",
pages = "103--108",
journal = "Annals of Neurology",
issn = "0364-5134",
publisher = "John Wiley and Sons Inc.",
number = "1",
}